U.S. BioDefense working with NIH to commercialize new inoculation technique

Published 16 November 2005

U.S. BioDefense (OTC Bulletin Board: UBDE) is working with the National Institutes of Health (NIH) to evaluate a commercialization plan for its universal viral inactivation technique. The strategy, which was developed with support from the National Cancer Institute, involves making an anti-viral agent from a viral sample that has been deactivated. Most vaccines in use today are produced from weakened viral samples that retain some potential to infect the patient, and do not always protect against the full form of the virus. U.S. BioDefense claims that in addition to overcoming these shortcomings by basing an inoculation on a sample that more closely matches the wild form, the new technique will also speed the time required to develop a vaccine.

It is our belief that we need to act now before an influenza pandemic is at hand. By utilizing a new method, we can potentially generate vaccines that are more effective than current ones at a faster rate,” said Dr. Cyndi Chen, Director of Research.

-read the release